MET and non-small cell lung carcinoma: These findings suggest future research investigating the merit of sHGF as a potential clinical biomarker to indicate administration of MET inhibitors in patients with NSCLC, or as a re-biopsy marker for patients treated with CC, may lead to the development of a new indicator of MET inhibitors and improve targeted therapies for lung cancer.